中国P站

The landscape of solid organ transplantation is continuously evolving, with a significant focus on optimizing patient outcomes through rigorous monitoring and individualized immunosuppression strategies. Early detection and precise management of complications such as graft rejection and drug toxicity are paramount to long-term graft survival and patient well-being. Recent advancements have underscored the importance of moving beyond traditional histological assessments to embrace more dynamic and personalized monitoring approaches. The review by Cabello-Veron et al. highlights the current state of monitoring for transplant rejection and drug toxicity, emphasizing the growing significance of non-invasive methods and the imperative for personalized immunosuppression. It points out the persistent challenges in differentiating between rejection and drug-induced injury and advocates for improved diagnostic tools and a deeper understanding of drug mechanisms [1].

Maltzman et al. investigated the incidence and risk factors associated with calcineurin inhibitor (CNI)-induced nephrotoxicity specifically in liver transplant recipients. Their research focused on the influence of genetic polymorphisms and early post-transplant management, suggesting that careful titration of CNIs and consideration of genetic predispositions can mitigate long-term renal damage [2].

De Faria et al. provided a comprehensive review of the mechanisms underlying mammalian target of rapamycin inhibitor (mTORi) toxicity in solid organ transplantation. They detailed common adverse events, including metabolic disturbances, wound healing complications, and hematological abnormalities, and offered practical guidance for managing these toxicities through dose adjustments and alternative strategies [3].

D'Amico et al. explored the utility of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive biomarker for the detection and monitoring of acute kidney allograft rejection. Their findings indicated that elevations in dd-cfDNA levels can precede histological evidence of rejection, presenting a promising avenue for early intervention and a potential reduction in the reliance on protocol biopsies [4].

Rossi et al. addressed the critical challenge of distinguishing antibody-mediated rejection (AMR) from other forms of graft dysfunction in heart transplant recipients. They stressed the necessity of a multifaceted diagnostic approach, incorporating serological testing for donor-specific antibodies, C4d deposition, and emerging molecular diagnostics to guide effective treatment [5].

Russo et al. focused on the management of post-transplant lymphoproliferative disorder (PTLD), a serious complication arising from immunosuppression. Their article outlined diagnostic criteria, identified risk factors, and discussed current treatment strategies, emphasizing the delicate balance required between reducing immunosuppression and minimizing the risk of graft rejection [6].

Sacco et al. evaluated the efficacy and safety of switching from calcineurin inhibitors to mTOR inhibitors in liver transplant recipients who experienced significant CNI-related toxicity. Their retrospective analysis reported favorable outcomes, including reduced nephrotoxicity and improved graft survival in carefully selected patient cohorts [7].

Molinar et al. examined the intricate relationship between viral infections and graft rejection in solid organ transplant recipients. They highlighted how specific viral infections can potentiate immune responses, contributing to graft dysfunction, and underscored the importance of consistent viral monitoring and prompt management [8].

Bertolini et al. introduced a novel approach utilizing circulating exosomal microRNAs (miRNAs) as potential biomarkers for the early detection of acute kidney injury in transplant patients. Their study identified specific miRNA signatures linked to drug-induced nephrotoxicity, laying the groundwork for non-invasive monitoring strategies [9].

Costa et al. reviewed the management of immunosuppression in kidney transplant candidates and recipients with high levels of sensitization. They detailed strategies to overcome immunological barriers, such as desensitization protocols and novel immunosuppressive agents, while acknowledging the associated increased risks of infection and drug toxicity [10].

Description

The monitoring of solid organ transplant recipients necessitates a comprehensive strategy that integrates advanced diagnostic tools with personalized therapeutic approaches. The evolution from traditional histological assessments to non-invasive biomarkers and tailored immunosuppression regimens is crucial for improving graft survival and patient outcomes. This multi-faceted approach aims to address the complexities of distinguishing between graft rejection and drug-induced toxicity, which remain significant clinical challenges. Cabello-Veron et al. provide an overview of the current landscape in monitoring for transplant rejection and drug toxicity, emphasizing the increasing role of non-invasive methods and the importance of personalized immunosuppression. They highlight the difficulties in differentiating rejection from drug-induced injury, advocating for enhanced diagnostic tools and a better understanding of drug mechanisms [1].

Maltzman et al. investigate the incidence and risk factors for calcineurin inhibitor (CNI)-induced nephrotoxicity in liver transplant recipients, with a particular focus on the impact of genetic polymorphisms and early post-transplant management. Their findings suggest that judicious CNI titration and consideration of genetic susceptibility can help mitigate long-term renal dysfunction [2].

De Faria et al. review the mechanisms of mammalian target of rapamycin inhibitor (mTORi) toxicity in solid organ transplantation, detailing common adverse events such as metabolic disturbances, wound healing issues, and hematological abnormalities. They offer practical guidance for managing these toxicities through dose adjustments, monitoring, and alternative immunosuppressive strategies [3].

D'Amico et al. assess the utility of donor-derived cell-free DNA (dd-cfDNA) as a non-invasive biomarker for the detection and monitoring of acute kidney allograft rejection. Their research indicates that rising dd-cfDNA levels can precede histological evidence of rejection, suggesting its potential as a tool for early intervention and reducing the need for routine protocol biopsies [4].

Rossi et al. address the challenges in differentiating antibody-mediated rejection (AMR) from other causes of graft dysfunction in heart transplant recipients. They underscore the importance of a comprehensive diagnostic approach, including serological testing for donor-specific antibodies, C4d deposition, and evolving molecular diagnostics, to guide appropriate treatment decisions [5].

Russo et al. focus on the management of post-transplant lymphoproliferative disorder (PTLD), a serious complication linked to immunosuppression. Their article discusses diagnostic criteria, risk factors, and current treatment strategies, emphasizing the need to judiciously balance immunosuppression reduction with the risk of graft rejection [6].

Sacco et al. evaluate the efficacy and safety of switching from calcineurin inhibitors to mTOR inhibitors in liver transplant recipients experiencing significant CNI-related toxicity. They report positive outcomes, including reduced nephrotoxicity and improved graft survival, in patients managed with this switch [7].

Molinar et al. discuss the complex interplay between viral infections and graft rejection in solid organ transplant recipients. They highlight how certain viral infections can exacerbate immune responses and contribute to graft dysfunction, stressing the importance of vigilant viral monitoring and prompt management [8].

Bertolini et al. present a novel approach using circulating exosomal microRNAs (miRNAs) as potential biomarkers for the early detection of acute kidney injury in transplant patients. Their study identifies specific miRNA signatures associated with drug-induced nephrotoxicity, paving the way for non-invasive monitoring [9].

Costa et al. review the management of immunosuppression in highly sensitized kidney transplant candidates and recipients. They cover strategies to overcome immunological barriers, such as desensitization protocols and novel immunosuppressive agents, while acknowledging the increased risks of infection and drug toxicity associated with these approaches [10].

Conclusion

Solid organ transplantation management increasingly relies on sophisticated monitoring techniques and personalized immunosuppression to optimize graft survival and patient outcomes. Key challenges include distinguishing between graft rejection and drug toxicity, with advancements in non-invasive biomarkers like donor-derived cell-free DNA and exosomal microRNAs showing promise for early detection. Research is exploring genetic predispositions to drug-induced nephrotoxicity, mechanisms of drug toxicity from calcineurin inhibitors and mTOR inhibitors, and strategies for managing highly sensitized patients. Viral infections are recognized as contributors to graft dysfunction, necessitating vigilant monitoring. Strategies for managing complications such as post-transplant lymphoproliferative disorder and addressing drug-related toxicities by switching immunosuppressive agents are also discussed, highlighting the critical balance between immunosuppression and rejection risk.

References

1. Claudio PC, Nadege GL, Valerie BPD. (2022) .J Clin Exp Transplant 1:21-31.

   , ,

2. Jonathan SM, Roslyn JD, Elizabeth MBB. (2023) .Am J Transplant 23:e17084.

   , ,

3. Alice RVDF, Maria GRDS, Pedro HSDA. (2021) .Transplant Rev (Orlando) 35:100607.

   , ,

4. Giuseppe GD, Paolo MR, Marco GM. (2020) .Clin Transplant 34:e13800.

   , ,

5. Laura MPR, Marco LB, Simone RF. (2023) .J Heart Lung Transplant 42:739-748.

   , ,

6. Francesco LR, Andrea MC, Valeria GP. (2021) .Transplantation 105:1099-1110.

   , ,

7. Roberto GS, Luigi GF, Stefano GC. (2022) .Liver Transpl 28:1415-1423.

   , ,

8. Silvia GM, Davide GDB, Chiara GM. (2023) .Front Immunol 14:1133172.

   , ,

9. Marco GB, Giulia GC, Paolo GR. (2022) .J Extracell Vesicles 11:1514686.

   , ,

10. Emanuele GC, Chiara GN, Federico GL. (2021) .Kidney Int 100:1235-1245.

    , ,